2-[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(4-fluorophenyl)ethyl]thioacetic acid | 956368-72-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(4-fluorophenyl)ethyl]thioacetic acid
• 英文别名: {[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(4-fluorophenyl)ethyl]thio}acetic acid；2-[(2R)-2-(4-fluorophenyl)-2-(1,1,2,2-tetramethyl-1-silapropoxy)ethylthio]acetic acid；(R)-2-((2-((Tert-butyldimethylsilyl)oxy)-2-(4-fluorophenyl)ethyl)thio)acetic acid；2-[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(4-fluorophenyl)ethyl]sulfanylacetic acid
• CAS: 956368-72-2
• 化学式: C₁₆H₂₅FO₃SSi
• 分子量: 344.523
• InChiKey: ZEYFZZJBDSTVDQ-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.71
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(4-fluorophenyl)ethyl]thioacetic acid 在 四丁基氟化铵 4-二甲氨基吡啶 、 Oxone 、 N,O-双三甲硅基乙酰胺 、 氢氟酸 、 三甲基乙酰氯 、 四氯化钛 、 N,N-二异丙基乙胺 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  WO2006/121861

  摘要：

  公开号：
• 作为产物：
  描述：

  2-bromo-1-(4-fluorophenyl)ethanol 在 咪唑 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 生成 2-[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(4-fluorophenyl)ethyl]thioacetic acid
  参考文献：
  名称：

  WO2006/121861

  摘要：

  公开号：

文献信息

• Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitor Activity
  申请人：Lemurell Malin

  公开号：US20090069285A1

  公开（公告）日：2009-03-12

  2-azetidinone derivatives and pharmaceutical compositions containing them. The compounds are useful in the treatment of hyperlipidemic conditions, atherosclerosis, Alzheimers' disease and cholesterol associated tumours.

  2-azetidinone衍生物及含有它们的制药组合物。这些化合物在治疗高脂血症、动脉粥样硬化、阿尔茨海默病和与胆固醇有关的肿瘤方面是有用的。
• 1-BIARYLAZETIDINONE DERIVATIVE
  申请人：Nakano Akira

  公开号：US20100125059A1

  公开（公告）日：2010-05-20

  The object of the present invention is to provide a compound having an excellent cholesterol-lowering effect and to provide a drug for the treatment, prevention of onset, or prevention of progress of lipid metabolism disorder, hyperlipidemia, or atherosclerosis. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof; or a medicament or a pharmaceutical composition, which contain the compound or the salt as an active ingredient.

  本发明的目的是提供一种具有出色的降低胆固醇作用的化合物，并提供一种用于治疗、预防脂质代谢紊乱、高脂血症或动脉粥样硬化的药物。该化合物由式(I)表示或其药学上可接受的盐；或包含该化合物或盐作为活性成分的药物或制药组合物。
• Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
  申请人：AstraZeneca AB

  公开号：US07842684B2

  公开（公告）日：2010-11-30

  The present invention provides 2-azetidinone derivatives, or pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof, comprising formula (I): wherein the substituents are as herein defined. The compounds possess cholesterol absorption inhibitory activity and are accordingly of value in the treatment of disease states associated with hyperlipidaemic conditions.

  本发明提供2-氮杂环己酮衍生物，或其药学上可接受的盐、溶剂、这些盐的溶剂和其前药，其化学式为（I）：其中取代基的定义如本文所述。这些化合物具有抑制胆固醇吸收的活性，因此在治疗与高脂血症相关的疾病状态方面具有价值。
• Selection and Development of a Route for Cholesterol Absorption Inhibitor AZD4121
  作者：Staffan Karlsson、J. Henrik Sörensen

  DOI：10.1021/op200314z

  日期：2012.4.20

  The development of a synthetic route to the cholesterol absorption inhibitor AZD4121 is presented. Key steps are a highly enantioselective CBS reduction, a stereospecific Staudinger reaction, an amine/lithium chloride mediated ester hydrolysis, and a resolution of a 50:50 diastereomeric mixture by recrystallization. The synthesis was accomplished in 10 linear steps, and the overall yield, when compared with the lead optimization (LO) route, was improved from 1% to 20%. All purifications of intermediates through preparative HPLC or silica gel chromatography were avoided. This was possible since many of the intermediates along the route could be used as such in the next step until an intermediate with suitable crystalline properties could be identified and purified through crystallization.
• EP2133347
  申请人：——

  公开号：——

  公开（公告）日：——